{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:07:16Z","timestamp":1785550036085,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40262-025-01555-8","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:34:08Z","timestamp":1753446848000},"page":"1507-1515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic\u2013Pharmacoeconomic Evaluation"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3993-2898","authenticated-orcid":false,"given":"Fenna","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-0730","authenticated-orcid":false,"given":"Eric J. F.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A. J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-0026","authenticated-orcid":false,"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-5858","authenticated-orcid":false,"given":"Thijs Oude","family":"Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8201-6599","authenticated-orcid":false,"given":"Jeroen J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-7530","authenticated-orcid":false,"given":"Stijn L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-1769","authenticated-orcid":false,"given":"Wietske","family":"Kievit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-2153","authenticated-orcid":false,"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8201","authenticated-orcid":false,"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"15_suppl","key":"1555_CR1","doi-asserted-by":"publisher","first-page":"e14143","DOI":"10.1200\/JCO.2020.38.15_suppl.e14143","volume":"38","author":"M Cinausero","year":"2020","unstructured":"Cinausero M, Garattini SK, Minisini AM, Valent F, Riosa C, Iacono D, et al. Incremental oncology workload generated by immunotherapy in the first-year of treatment. J Clin Oncol. 2020;38(15_suppl):e14143. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e14143.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1555_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44923","volume":"5","author":"A Desai","year":"2022","unstructured":"Desai A, Scheckel C, Jensen CJ, Orme J, Williams C, Shah N, et al. Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020. JAMA Netw Open. 2022;5(1): e2144923. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44923.","journal-title":"JAMA Netw Open"},{"key":"1555_CR3","unstructured":"AstraZeneca. Highlights of prescribing information: Durvalumab (IMFINZI\u00ae). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761069s043lbledt.pdf. Accessed 10 Sep 2024."},{"key":"1555_CR4","unstructured":"AstraZeneca. Annual Report 2017. 2017. https:\/\/www.astrazeneca.com\/investor-relations\/annual-reports\/annual-report-2017.html. Accessed 10 Sep 2024."},{"key":"1555_CR5","unstructured":"European Medicines Agency. Public Assessment Report (EPAR): Durvalumab (IMFINZI\u00ae). 2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/imfinzi-epar-public-assessment-report_en.pdf. Accessed 10 Sep 2024."},{"key":"1555_CR6","unstructured":"European Medicines Agency. Public Assessment Report (EPAR): Durvalumab (IMFINZI\u00ae)\u2014variation. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/imfinzi-h-c-4771-ii-0014-g-epar-assessment-report-variation_en.pdf. Accessed 10 Sep 2024."},{"key":"1555_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jclepro.2018.11.204","volume":"214","author":"L Belkhir","year":"2019","unstructured":"Belkhir L, Elmeligi A. Carbon footprint of the global pharmaceutical industry and relative impact of its major players. J Clean Prod. 2019;214:185\u201394. https:\/\/doi.org\/10.1016\/j.jclepro.2018.11.204.","journal-title":"J Clean Prod"},{"issue":"8","key":"1555_CR8","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/jan.15671","volume":"79","author":"L Rodriguez-Jimenez","year":"2023","unstructured":"Rodriguez-Jimenez L, Romero-Martin M, Spruell T, Steley Z, Gomez-Salgado J. The carbon footprint of healthcare settings: a systematic review. J Adv Nurs. 2023;79(8):2830\u201344. https:\/\/doi.org\/10.1111\/jan.15671.","journal-title":"J Adv Nurs"},{"issue":"4","key":"1555_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpt.982","volume":"103","author":"PG Baverel","year":"2018","unstructured":"Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631\u201342. https:\/\/doi.org\/10.1002\/cpt.982.","journal-title":"Clin Pharmacol Ther"},{"key":"1555_CR10","unstructured":"Zorginstituut Nederland. Farmacotherapeutisch rapport durvalumab (Imfinzi\u00ae) bij de behandeling van lokaal gevorderde, irresectabele niet-kleincellig longkanker (NSCLC) in volwassenen bij wie de ziekte geen progressie heeft vertoond na platinumbevattende chemotherapie met radiotherapie. 2019. https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/adviezen\/2019\/04\/01\/pakketadvies-sluisgeneesmiddel-durvalumab-imfinzi-voor-volwassenen-met-lokaal-gevorderd-irresectabel-niet-kleincellig-longcarcinoom\/Pakketadvies+durvalumab+%28Imfinzi%29.pdf. Accessed 10 Sep 2024."},{"key":"1555_CR11","unstructured":"Zorginstituut Nederland. Medicijnkosten.nl\u2014Durvalumab. https:\/\/www.medicijnkosten.nl\/zoeken?trefwoord=durvalumab. Accessed 5 Sep 2024."},{"key":"1555_CR12","unstructured":"Zorginstituut Nederland. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen-Herziene versie 2024. 2024. https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/Verdiepingsmodule+Kostenhandleiding+%28versie+2024%29.pdf. Accessed 5 Sep 2024."},{"key":"1555_CR13","unstructured":"OLVG Laboratoria BV. Tarieven (basis) 2024. https:\/\/webshare.zenya.work\/ls2m5z7n5cgqhrfn\/Document.aspx?websharedocumentid=2be63bc8-6691-4c9f-aa7e-6184b1f14f0e. Accessed 5 Sep 2024."},{"key":"1555_CR14","unstructured":"RHMDC. Tarieven. https:\/\/rhmdc.nl\/tarieven. Accessed 5 Sep 2024."},{"key":"1555_CR15","unstructured":"Abbexa. Durvalumab ELISA Kit. https:\/\/www.abbexa.com\/durvalumab-elisa-kit. Accessed 5 Sep 2024."},{"key":"1555_CR16","unstructured":"Abcam. Durvalumab (Human) ELISA Kit. https:\/\/www.abcam.com\/en-us\/products\/elisa-kits\/durvalumab-human-elisa-kit-ab280328. Accessed 5 Sep 2024."},{"key":"1555_CR17","unstructured":"Abnova. Durvalumab (Human) ELISA Kit (Quantitative). https:\/\/www.abnova.com\/en-global\/product\/detail\/ka6857. Accessed 5 Sep 2024."},{"key":"1555_CR18","unstructured":"AntibodySystem. Durvalumab ELISA Kit (KDJ70103). https:\/\/www.antibodysystem.com\/product\/8228.html. Accessed 5 Sep 2024."},{"key":"1555_CR19","unstructured":"Biovision. BioSim\u2122 Durvalumab (Human) ELISA Kit. https:\/\/transcriptionfactor.org\/biosim\/biosim-durvalumab-human-elisa-kit\/. Accessed 5 Sep 2024."},{"key":"1555_CR20","first-page":"92","volume-title":"Collectieve Arbeidsovereenkomst Universitair Medische Centra 2024 t\/m 2025","author":"Nederlandse Federatie van Universitair Medische Centra","year":"2024","unstructured":"Nederlandse Federatie van Universitair Medische Centra. Collectieve Arbeidsovereenkomst Universitair Medische Centra 2024 t\/m 2025. Utrecht: NFU; 2024. p. 92\u2013102."},{"key":"1555_CR21","unstructured":"ProteoGenix. Durvalumab ELISA Kit. 2024 [cited 05-09-2024]. https:\/\/www.proteogenix.science\/product\/durvalumab-elisa-kit\/."},{"key":"1555_CR22","first-page":"121","volume-title":"Collectieve Arbeidsovereenkomst Ziekenhuizen 2023\u20132025","author":"Nederlandse Vereniging van Ziekenhuizen","year":"2023","unstructured":"Nederlandse Vereniging van Ziekenhuizen. Collectieve Arbeidsovereenkomst Ziekenhuizen 2023\u20132025. Utrecht: NVZ; 2023. p. 121\u20139."},{"key":"1555_CR23","first-page":"55","volume-title":"Arbeidsvoorwaarden Medisch Specialisten (AMS) 2023","author":"Nederlandse Vereniging van Ziekenhuizen","year":"2023","unstructured":"Nederlandse Vereniging van Ziekenhuizen. Arbeidsvoorwaarden Medisch Specialisten (AMS) 2023. Utrecht: NVZ; 2023. p. 55\u20139."},{"key":"1555_CR24","unstructured":"Centraal bureau voor de Statistiek. StatLine. Consumentenprijzen; prijsindex 2015. https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/83131NED\/table?ts=1723560344437. Accessed 02 Sep 2024."},{"issue":"3","key":"1555_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-023-00958-6","volume":"18","author":"R Ter Heine","year":"2023","unstructured":"Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, et al. A systematic evaluation of cost-saving dosing regimens for therapeutic antibodies and antibody-drug conjugates for the treatment of lung cancer. Target Oncol. 2023;18(3):441\u201350. https:\/\/doi.org\/10.1007\/s11523-023-00958-6.","journal-title":"Target Oncol"},{"key":"1555_CR26","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Oncology Center of Excellence. Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry. 2022. https:\/\/www.fda.gov\/media\/151745\/download. Accessed 3 Sep 2024."},{"key":"1555_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115564","volume":"225","author":"P Jimenez-Labaig","year":"2025","unstructured":"Jimenez-Labaig P, Mohamed F, Tan NJI, Sanna I, El Bairi K, Khan SZ, et al. Expanding access to cancer immunotherapy: a systematic review of low-dose PD-(L)1 inhibitor strategies. Eur J Cancer. 2025;225: 115564. https:\/\/doi.org\/10.1016\/j.ejca.2025.115564.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1555_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01182-3","volume":"15","author":"C Maritaz","year":"2022","unstructured":"Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol. 2022;15(1): 6. https:\/\/doi.org\/10.1186\/s13045-021-01182-3.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1555_CR29","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/bcp.14369","volume":"86","author":"CJ Peer","year":"2020","unstructured":"Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. Br J Clin Pharmacol. 2020;86(9):1769\u201377. https:\/\/doi.org\/10.1111\/bcp.14369.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01555-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:49:06Z","timestamp":1759146546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01555-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1555"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01555-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"14 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interest: A.v.d.W. has relationships with AstraZeneca, Boehringer Ingelheim GmbH, Pfizer Inc, F. Hoffmann-La Roche Ltd, Takeda Oncology, Bristol Myers Squibb Co., and Eli Lilly and Company, involving consulting, advisory roles, funding grants, and speaking fees. D.D. has consulting and speaking engagements with Bristol Myers Squibb Co., Merck & Co. Inc., AstraZeneca, Roche, and Pfizer. M.v.d.H. received financial support from the Radboudumc Department of Respiratory Diseases. The parties of interest had no role in the study\u2019s design, data collection, analysis, interpretation, manuscript writing, or the decision to publish. Non-financial interest: A.v.d.W. holds a fiduciary role on the board of the ROS1ders advocacy group. R.t.H. is affiliated with Radboud University Medical Center. The parties of interest had no role in the study\u2019s design, data collection, analysis, interpretation, manuscript writing, or the decision to publish. Editorial Board membership: D.M. is an editorial board member of Clinical Pharmacokinetics. D.M. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. No interest: The remaining authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The population pharmacokinetic model code is included as Supplementary Information.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"No funds, grants, or other support was received.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Data is included as Supplementary Information.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"F. de Vries: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Validation, Writing\u2014original draft. E.J.F. Franssen: Conceptualization, Supervision, Resources, Writing\u2014review and editing. A.A.J. Smit: Conceptualization, Writing\u2014review and editing. D.J.A.R. Moes: Writing\u2014review and editing. A.J. van der Wekken: Writing\u2014review and editing. T. Oude Munnink: Writing\u2014review and editing. J.J.M.A. Hendrix: Writing\u2014review and editing. D.W. Dumoulin: Writing\u2014review and editing. S.L.W. Koolen: Writing\u2014review and editing. W. Kievit: Methodology, Writing\u2014review and editing. M.M. van den Heuvel: Conceptualization, Writing\u2014review and editing. R. ter Heine: Conceptualization, Methodology, Supervision, Resources, Writing\u2014original draft. All authors have provided their formal approval for this submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}